All In Biotech

NDA 050793 · Padagis US

Clindesse

Clindamycin Phosphate · Vaginal

Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Nov 30, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

3,697

2,334 serious, 269 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 30, 2025.

Clindesse is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in non-pregnant women ( 1.1 ) 1.1 Treatment of Bacterial Vaginosis Clindesse is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis) in non-pregnant women.

Mechanism: Clindamycin is an antibacterial drug [see Clinical Pharmacology, Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 30, 2004 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLabelLetter
1 products under this application
  • CLINDESSE · CLINDAMYCIN PHOSPHATE EQ 2% BASE · CREAM, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective382
  • rash260
  • drug hypersensitivity230
  • off label use230
  • nausea196
  • diarrhoea193
  • pain182
  • fatigue175
  • pruritus174
  • condition aggravated139
  • headache120
  • dyspnoea118

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200548
200658
200714
200825
200948
201086
201175
2012102
2013110
2014107
2015131
2016247
2017216
2018243
2019294
2020214
2021197
2022297
2023306
2024286
2025310
2026264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clindesse (Clindamycin Phosphate)

2024 spending

$56K

Beneficiaries

182

251 claims

Per beneficiary

$308

$27.16 per unit

View as table
YearSpending
2020$72,016
2021$66,495
2022$53,595
2023$37,814
2024$56,115

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,208 on PubMed

Sponsor: Padagis US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.